Physician profile
Megan Sim
NPI 1518631183
$2,661.87
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $583 · 2022: $2,079.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $292.95 | 2021-2022 | |
| Amgen INC. | $270.69 | 2021-2022 | |
| Incyte Corporation | $157.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $154.25 | 2022 | |
| Seagen INC. | $137.09 | 2021-2022 | |
| Genzyme Corporation | $135.96 | 2021-2022 | |
| Genentech USA, INC. | $133.40 | 2021-2022 | |
| Celgene Corporation | $78.23 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $76.06 | 2022 | |
| Janssen Biotech, INC. | $73.88 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.36 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $68.49 | 2022 | |
| Myovant Sciences INC. | $61.64 | 2021 | |
| Ge Healthcare | $59.96 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.91 | 2021-2022 |
Show all 45 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Sim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.